論文 - 藤原 一男
-
Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, von Büdingen HC, Klingelschmitt G, Stokmaier D, Bennett JL.
Neurol Neuroimmunol Neuroinflamm. 10 ( 1 ) e200071 2022年12月
-
Diagnosis and classification of optic neuritis.
Petzold A, Fraser C, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov M, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi P, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, DeSeze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Froment Tilikete C, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Hernández Martínez de Lapiscina E, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales A, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, Van Pesch V, Wang AG, Wattjes M, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT.
Lancet Neurol. 21 ( 12 ) 1120 - 1134 2022年12月
-
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC on behalf of the N-MOmentum study investigators.
EBioMedicine. 86 104321 2022年12月
-
Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).
Kissani N, Ouadika1 RJB, Kishk NA, Chaymae O, Ibrahim EAA, Maiga Y, Paul R, Daniel GM, Hamid A, Assogba K, Gaye NM, Hor JY, Tegueu CK, Marignier R, Palace J, Weinshenker BG, Ragab AH, Fujiharaa K. Neuromyelitis Optica Spectrum Disorders in Africa (A Narrative Review of 622 Cases).
Open Access Library J. e9649 2022年9月
-
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.
J Neurol. 269 ( 6 ) 3136 - 3146 2022年6月
-
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.
Neurol Ther. 11 ( 1 ) 123 - 135 2022年5月
-
Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: a case series.
Yamamura T, Araki M, Fujihara K, Okuno T, Misu T, Guo YC, Hemingway C, Matsushima J, Sugaya N, Yamashita M, von Büdingen HC, Miyamoto K.
Mult Scler Relat Disord. 61 103772 2022年5月
-
RGMa signal in macrophages induces neutrophil-related astrocytopathy in NMO.
4. Iwamoto S, Itokazu T, Sasaki A, Kataoka H, Tanaka S, Hirata T, Miwa K, Suenaga T, Takai Y, Misu T, Fujihara K, Yamashita T.
Ann Neurol. 91 ( 4 ) 532 - 547 2022年4月
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.
Mult Scler. 28 ( 3 ) 480 - 486 2022年3月
-
Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ.
Neurol Ther. 11 ( 1 ) 123 - 135 2022年3月
-
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Róisín Armstrong R, Wingerchuk DM, and the PREVENT Study Group.
Mult Scler. 28 ( 3 ) 480 - 486 2022年3月
-
AQP4-IgG seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
1. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk D, Green AJ, Fujihara K, Cutterj G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC, on behalf of the N-MOmentum study investigators.
Mult Scler Relat Disord 57 103356 2022年1月
-
Difference of anti-viral immunity induced by two mRNA vaccines: Implications in MS patients treated with anti-CD20-depleting therapy.
Tanaka M, Fujihara K.
Clin Exp Neuroimmunol ( 13 ) 5 - 6 2022年
-
Autoantibodies in central nervous system and neuromuscular autoimmune disorders A narrative review.
Joen MY, Seok JM, Fujihara K, Kim BJ.
Precis Future Med. 6 ( 2 ) 105 - 116 2022年
-
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Takahashi T, Takai Y, Nishiyama S, Kaneko K, Fujimori J, Ishii T, aoki M, Nakashima I.
J Neurol. 2021年11月
-
White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments.
Akaishi T. Misu T, Fujihara K. Nakaya N, Nakamura T, Kogure M, Hatanaka R, Itabashi F, Kanno I, Takahashi T, Kuroda H, Fujimori J, Takai Y, Nishiayama S, Kaneko K, Ishii T, Aoki M, Nakashima I, Hozawa A.
Sci Rep. 11 ( 1 ) 22357 2021年11月
-
GRP78 antibodies are associated with blood-brain barrier-breakdown in anti-myelin oligodendrocyte glycoprotein antibody-associated disorder.
Shimizu F, Ogawa R, Mizukami Y, Watanabe K, Hara K, Kadono C, Takahashi T, Misu T, Takeshita Y, Sano Y, Fujisawa M, Maeda T, Nakashima I, Fujihara K, Kanda T.
Neurol Neuroimmunol Neuroinflamm. 9 ( 1 ) e1038 2021年11月
-
Patient-reported burden of symptoms in neuromyelitis optica: a secondary analysis on pain and quality of life.
Fujihara K, Hattori S, Kleiter I, Levy M, Matsuda Y, Mitsutake A, Haramura M, Palace J, Yamamura T. on behalf of The Guthy-Jackson Charitable Foundation NMOSD Quality of Life Working Group.
J Neurol Sci. 428 117546 2021年9月
-
MOG-antibody associated disease.
Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Dphil HA, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B.
Lancet Neurol. 20 ( 9 ) 762 - 772 2021年9月
-
Five-year visual outcome after optic neuritis in anti-MOG antibody-associated disease.
Akaishi T, Himori N, Takeshita T, Misu T, Takahashi T, Takai Y, Nishiyama S, Fujimori J, Ishii T, Aoki M, Fujihara K, Nakazawa T, Nakashima I.
Mult Scler Relat Disord Mult Scler Relat Disord. 56 103222 2021年8月